




DEFICIENT GLYCOPROTEIN (CDG) 
SYNDROME PATIENT IN SOUTH 
AFRICA 
J A du Plessis, P J Pretorius, M M Lippert, D P Knoll, 
E Erasmus, F H van der Westhuizen, L J Mienie 
The carbohydrate-deficient glycoprotein (CDG) syndrome 
caused by congenital defects in glycoprotein anabolism is a 
relatively recently discovered group of diseases, with 
autosomal recessive inheritance and multisystemic 
involvement.' Seven different subtypes of this syndrome have 
been described' to date and clinical symptoms may vary within 
these subtypes. Very little is known about the genetic basis of 
these defects, but the enzyme defect has been determined for 
three of the subtypes, namely types IA,' IB' and II,' and the 
enzyme assays can be used to assist in the diagnosis of these 
variants. 
A common characteristic of the subtypes is a deficiency in 
the carbohydrate moiety of glycoproteins, which are involved 
in various biochemical processes.• The clinical features of 
patients with defects of the glycoprotein anabolism are less 
distinct and no abnormal oligosaccharides are present in the 
urine of these patients.7 These deficiencies can, however, be 
readily observed in the serum glycoprotein transferrin," 
although several if not all other glycoproteins are affected by 
this defect. !so-electric focusing (IEF) of transferrin, followed 
by irnrnunodetection, shows a cathodal shift as a consequence 
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of partial deficiency of sialic acid5 and is commonly used as a 
reliable diagnostic test for the CDG syndrome. The partial 
deficiency of sialic acid is the result of a lack of two or four of 
the terminal trisaccharides normally present on the transferrin 
molecule.'_. Transferrin is widely used as a marker for the CDG 
syndromes, and preliminary results indicate a relatively high 
incidence of this disease in European countries'·' 
Both the nervous system and other organs are involved in 
the pa thology of these diseases.' The neurological picture 
comprises mild to severe psychomotor retardation, 
olivopontocerebellar atrophy, retinal degradation, seizures, 
stroke-like episodes and peripheral neuropathy.'0•11 The heart is 
also affected and patients may show cardiomyopathy or 
pericardia! effusions.'·'0 Hepatomegaly has also been described 
in these patients•.u.u Facial dysmorphism, skeletal 
abnormalities and abnormal subcutaneous adipose tissue 
distribution, together with inverted nipples, are also frequently 
found in CDG patients." Coagulation defects such as 
thrombosis or excessive bleeding are common,13 along with 
failure to thrive and feeding difficulties such as vomiting and 
diarrhoea' ·'0•13 Infantile spasms and abnormal skin 
pigmentation have also been reported." 
In general, serum glycoprotein concentrations or enzyme 
activities are decreased," though a few (follicle-stimulating 
hormone (FSH) and arylsulphatase A) may be increased and 
o thers (transferrin) may be normal.'-" Serum transarninases 
may be increased," while levels of coagulation factors and 
plasma albumin may be decreased' 0•12 Serum levels of growth 
hormone and insulin may also be increased,'0•12 while some 
patients may be anaemic." 
The most common biochemical manifestation of the CDG 
syndromes is raised levels of carbohydrate deficient 
transferrin (CDT) in serurn.10•12 In healthy controls serum 
transferrin consists mainly of tetrasialotransferrin, with an iso-
electric point (pi) of 5.4, and to a lesser extent of 
pentasialotransferrin with a pi of 5.3 and tri- and 
disialo transferrin with pis of 5.6 and 5.7 respectively.5 Patients 
suffering from the CDG syndromes show decreased levels of 
anodal transferrin isoforms and pronouncedly increased levels 
of cathodal transferrin isoforrns, e.g. d isialotransferrin with a 
pi of 5.7 and asialotransferrin with a pi of 5.9.12 
C ASE REPORT 
The patient, female and an only child, was born by normal 
delivery after a normal pregnancy and weighed 3 370 gat 
birth. At birth she was 53 ern in length, with a head 
circumference of 34 ern. o immediate neonatal difficulties 
arose. At 3 months of age a squint was observed during a spell 
of otitis media. She smiled reciprocally at 6- 8 weeks of age 
and laughed aloud at 3 months. Axial hypotonia had been 
noticed and therapy was administered . At 4Vz months clearer 
deviances were noted, namely floppy neck, poor eye contact, 
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poor visual pursuit and poor motor activity from lying prone. 
At 51/2 months epileptic seizures set in, with prolonged clonic 
jerking of the right shoulder and arm, occurring three times in 
24 hours. Medication-refractory seizures of generalised tonic-
clonic nature occurred repetitively over 6 days. Apnoeic spells 
also occurred and she showed poor throat clearance, with 
pharyngeal pooling. She fed poorly and by that time skull 
growth had decelera ted. 
At 61/2 months the patient was admitted to hospital in a 
stuporous tate. Her muscle mass was low and pronounced 
hypotonia was present. Upper motor neuron dysfunction was 
observed, and she was puffy and mildly anaemic. 0 
visceromegaly was seen and magnetic resonance imaging 
(MRI) scanning showed only mild cortical atrophy. She was of 
small stature, weighing 6 600 g, 67 em in length and with a 
head circumference of 41.5 em. Her visually evoked potentials 
were greatly impaired, but the electroretinogram (ERG) was 
normal. On fundoscopy a severe maculopathy was observed. 
Over time seizure control remained difficult, in spite of various 
polypharmacological regimens. There was progressive growth 
impairment of the skull and spasticity set in, affecting mainly 
the lower extremities. Scoliosis developed and articular 
hypermobility of the upper limbs was noted. Her dis tal limbs 
became long and narrow, while breast tissue developed some 
mass with inverted nipples. o cardiac or liver d ysfunction 
was recognised . 
At age 4 years and 10 months she has gone for 3 months 
without seizures and greater responsiveness has been observed . 
She is functionally blind, with intact pupil responses and blink-
to-menace response. Severe psychomotor retardation has set in 
and she can sit independently, but carmot crawl. Blood samples 
from the patient were obtained and IEF of transferrin w as 
performed. 
I NVESTIGATIO N S 
Samples from the patient were obtained as blood spots on fil ter 
paper cards and transferrin was eluted from the paper in 100 p] 
of water at 4°C for 24 - 36 hours. Of this eluate, 50 p] was 
incuba ted with 200 )1M iron (III) ci tra te at 37°C for 20 minutes, 
after which 1.5 p] of the incubation mixture was loaded in the 
sample applicator and placed on a Phastgel IEF, pH 4 - 6.5. !so-
electric focusing of the samples was performed according to the 
IEF programme u · ed by Hackler and co-worker .16 After 
electrophoresis, 50 !1-i of goat-antihuman transferrin dilu ted 
with 50 !1-i of sodium chloride was spread evenly over the gel 
and left at room temperature for 40 minutes. The gel was 
washed overnight in 0.15M sodium chloride. Afterwards the 
gel was washed in water for 30 minutes, the sample was fixed 
in the gel for 30 minutes wi th 20% tri-chloroacetic acid and 
washed in water for 30 minutes. The gel was stained with 
Coomassie Brilliant Blue for 30 minutes and des tained with 
ethanol and acetic acid for 30 minutes, after which the gel was 
dried. 
R ES ULTS . 
Fig. 1 shows the results of IEF of samples from controls (lanes 1 
and 6), positive controls for CDG type I (lanes 2 and 3), a 
positive control for CDG type ll (lane 5) and the p atient (lane 
4). In the control samples the normal transferrin pattern can be 
observed clearly and shows high levels of te trasialotransferrin, 
with lower levels of penta-, tri- and disialotransferrin . The 
positive control for CDG type II shows lower levels of 
tetrasialotransferrin and increased levels of tri- and 
disialotransferrin. The transferrin pattern of the patient shows a 
pronounced increase in the levels of di- and asialotrarJSferrin, a 
pattern that corresponds with the positive controls for CDG 
type I. Fig. 2 shows a photograph of the patient a t age 5. 
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Fig. 1. /so-electric foc using pattern of serum transferrin in normal controls 
(lanes 1 and 6), positive controls fo r CDG type I (lanes 2 and 3), positive 
controls for CDG type II (lane 5) and the patient (lane 4). In this figure 4, 2 
and 0 indicate different sialotransferrins, with 4 indicating 
tetrasialotransferrin, 2 indicating disialotransferrin and 0 indicating 
asialotransferrin. The figure shows a gel stained with Coomassie Brilliant 
Blue after immunodetection. (Positive controls courtesy of Professor jaak 
Jaeken, Universitaire Ziekenlzuizen Leuven, Herestraat 49, 3000, l..euven, 
Belgium.) 
D ISCUSSIO 
This patient was shown to display abnormal transferrin 
patterns that correspond with known patterns for CDG type I. 
The diagnosis was subsequently confirmed by the laboratories 
of Dr J Jaeken (Universitaire Ziekenhuizen Leuven, Leuven, 
Belgium) and Dr M Duran (Wilhelmina Kinderziekenhuis, 
Utrecht, The etherlands) as either CDG type lA or IB. It is not 
possible to distinguish between CDG type lA and CDG type IB 
by mearJS of trarJSferrin analysis alone; for tha t purpose enzyme 
analysis is necessary.'·13 However, it is imp ortant to distinguish 
between the two subtypes, as CDG type IB can be treated and 
virtually all symptoms can be reversed after a few weeks of (D) 
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Fig. 2. The patient, suffering from CDG syndrome, at 5 years of age. 
+-mannose therapy (100 - 150 mg/ kg body mass five times per 
day)." This patient displayed normal enzyme activities for both 
enzymes used to distinguish between CDG lA and IB, i.e. 
phosphomannomutase (PMM) and phosphomannose 
isomerase (PMI) respectively. 
Since an extensive search of the literature failed to provide 
any information on the incidence of this disease in South 
Africa, it can be said that this is the first description of a South 
African patient presenting with the CDG syndrome. Judged on 
the transferrin pattern, this patient suffers from the type I form 
of the CDG syndrome, but in an atypical form according to the 
enzyme analyses. This opens up a whole new chapter in the 
study of genetic and metabolic diseases in this country, as the 
mere presence of this patient indicates that this disease may 
occur more frequently than expected, and since it is a recessive 
autosomal disease, several carriers may also be undiagnosed. 
In addition, preliminary studies have revealed that in a local 
institution for mentally retarded people, out of 15 patients who 
fitted the clinical description for the CDG syndrome, 5 revealed 
abnormal transferrin patterns. 
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It will take some time to determine the evidence of these 
syndromes in South Africa and to make a comparison with 
other countries. It will also take some time to create sufficient 
physician awareness to ensure speedy and accurate diagnosis 
of patients with this disease. Because it is a relatively new 
disease, it is also possible that many more subtypes may be 
discovered. A note of caution is appropriate at this point, since 
alcohol abuse, galactosaemia and some liver disease may also 
cause abnormal glycosylation of transferrin. 10 General clinical 
symptoms suggesting the presence of the CDG syndromes are 
psychomotor retardation, growth retardation, liver dysfunction, 
ataxia, cerebellar hypoplasia, skeletal abnormalities, feeding 
difficulties, peripheral neuropathy and other unexplained 
neurological symptoms. Testing for these syndromes can be 
done on both blood and serum samples dotted on filter paper 
cards, which can be sent by mail. 
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